Tel: 561-316-3330
Email: mdnewsmagazine@infomeddnews.com
Home Blog Page 4

How to Choose the Best Cardiologist in Bangalore for Your Heart Health

Cardiologist in Bangalore

If you experience mild or severe heart pain, it is time to visit a cardiologist. You need to choose the city’s top cardiologist for your care. Guaranteeing that you always receive excellent care and thorough treatment is essential. However, since you might not know where to start, this could be daunting. Here mentioned are the tips for choosing the best cardiologist in Bangalore:

Obtain A Recommendation 

Your family, acquaintances, and other medical professionals could make a big difference with a simple referral. Since they are more familiar with your health, your primary care physician should be able to guide you properly.

Family, friends, and coworkers are significant members of your circle of trust who can provide reliable recommendations. To have a conversation and learn more about them, put them on a list and schedule a meeting.

Examine The Quality of Hospitals 

There are numerous methods to assess a hospital’s quality of care. You should investigate how hospitals are compensated for their services. This will help you avoid paying extra for subpar care. Consider if the hospital offers a bundled payment plan as well. This plan mixes bundled payments for a patient’s care with payments.

Another significant factor is the hospital’s reputation. A hospital with a solid reputation for cardiac care should be chosen. A big hospital may not provide the quality of treatment you require.

Investigations into the Experience of Cardiologists 

Pay attention to the cardiologist’s area of expertise and whether it relates to the cardiac issue you are currently dealing with. Selecting a cardiologist Bangalore with expertise in your particular issue is essential. A cardiologist with experience is likely to provide better results and more effective therapy.

A cardiologist with extensive expertise can function effectively and make critical decisions confidently in trying circumstances. Ascertain how often they have conducted the surgery and what kinds of difficulties they have had. Another crucial factor is a cardiologist’s expertise with a particular technology.

Accessibility 

The growing need for cardiovascular care necessitates consideration of access to care. There are several methods for doing this. Programs can specify specific access objectives, like the proportion of new patients seen in five business days.

They should also monitor patterns in patient volume, such as the number of new and returning patients. These metrics are crucial when calculating market share growth. In addition to accessibility, location is important when selecting a cardiologist Bangalore.

Hospital Location

When you select your cardiologist, remember that you are also choosing your hospital. Therefore, be sure to consider the hospital’s location. As you choose a reputable hospital, note the hospital’s location as well.

Choose a nearby heart hospital in Bangalore for your rehabilitation because you may need to make multiple excursions. For added convenience, if you reside in Bangalore, look for the top heart physician there.

Style of Communication

Effective communication is the most important qualities you should look for in a cardiologist. Pay attention to vocal cues, such as how the individual greets and welcomes patients. Your cardiologist should be supportive and helpful to keep you relaxed and motivated. Developing relationships with patients is essential for cardiologists since they eventually result in successful diagnosis and therapy.

Your cardiologist needs to listen to you and politely answer your questions. They must be able to provide you with all the information you require to make wise health choices.

Examine the Cardiologist’s Qualifications 

Investigate a cardiologist’s qualifications before choosing one. A doctor’s training, expertise, and abilities are significantly reflected in their board certification. It guarantees the physician has the expertise required to deliver high-quality care.

A prospective cardiologist should have finished residency training in their specialty and graduated from a five-year medical college. Some will also complete a fellowship to concentrate better on a particular cardiology field. After training, a cardiologist may work at a hospital or private practice.

Read Patient Reviews 

You can learn more about the cardiologist by reading patient reviews online. You can filter through the data to learn more about patients’ experiences with parking issues, hospital wait times, and appointment scheduling. For instance, to learn more about a patient’s overall experience, investigate internet medical forums for cardiac surgeons in Bangalore.

Although you shouldn’t skip this phase, it should only make up a minor portion of your decision-making process. The reviews do not necessarily reflect the opinions of the majority of patients. So, better decision-making is essential.

Partial Words

Before choosing the right cardiologist Bangalore, you should read the above-mentioned points. Selecting the best medical staff and facility for your treatment is essential. Since you may have a lifelong relationship with your cardiologist, you should feel emotionally at ease with them. A competent cardiologist should have critical traits, including wisdom, kindness, and empathy. They should always maintain professionalism and be prepared to listen. The most crucial quality of a successful cardiologist is their capacity to give their patients reasonable hope.

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of its next generation drug eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.

“We are pleased to have FDA approval for our ELITE-BTK pivotal trial, thus allowing enrollment to begin for our next-generation MAGNITUDE scaffold. This will enable R3 Vascular to follow up on our positive first-in-human RESOLV1 study data which demonstrated excellent and promising results with 96% patency by DUS at 6-months,” said Christopher M. Owens, President and Chief Executive Officer of R3 Vascular. “Initiation of this trial will begin in Q1 2025 and will be conducted at up to 60 global clinical sites with 264 subjects, and upon favorable conclusion will allow the company to complete and pursue a PMA market application for MAGNITUDE with the FDA.”

MAGNITUDE is a next-generation bioresorbable scaffold with the potential to address one of the greatest needs of patients suffering from Chronic Limb-Threatening Ischemia due to below-the-knee PAD. R3 Vascular’s novel bioresorbable scaffolds are made from a unique, ultra-high molecular weight polylactic acid polymer. This polymer, combined with the company’s scaffold design and proprietary processing technology allows the sirolimus-coated scaffolds to be thinner, stronger, and more flexible even at larger diameters and longer lengths. R3 Vascular scaffolds are specifically engineered to ensure that they gradually and predictably absorb into the tissue, leaving nothing behind and enabling a more naturally functioning vessel.

Eric A. Secemsky, M.D., MSc, Director of Vascular Intervention at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and lead investigator for the ELITE-BTK pivotal trial said, “This is a much-anticipated trial given the advancements and advantages of this next-generation technology which has the potential to transform the field of peripheral interventions. We look forward to evaluating the impact of MAGNITUDE on patient outcomes and its ability to meet this growing clinical need.”

In May of 2024, the company announced the closing of its $87 million Series B financing round to support the ELITE-BTK IDE pivotal trial as well as additional research and development, global regulatory submissions, scale-up of manufacturing processes, and initial commercialization.

According to the American Heart Association PAD is a narrowing of the peripheral arteries that carry blood away from the heart to other parts of the body. The most common type is lower-extremity PAD, where blood flow is reduced to the legs and feet. The National Institutes of Health estimates PAD affects 8-12 million people in the U.S. and one in 20 Americans over the age of 50. The global peripheral vascular device market was valued at $12.9 billion in 2023 and is expected to reach $17.4 billion by 2030 with significant growth coming from the below-the-knee segment.

Boston Scientific Announces Agreement to Acquire Cortex, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company.

Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally.1

Cardiac ablation – the process of delivering energy to areas of the heart responsible for creating abnormal heart rhythms – is a common treatment for AF. During these procedures, physicians often use a mapping system to examine and analyze a heart’s electrical patterns to guide therapeutic applications. The OptiMap™ System developed by Cortex uses a basket catheter and proprietary algorithm to identify potential active AF sources, providing physicians with precise insights to efficiently deliver an individualized ablation strategy for their patients.

“We believe the addition of the Cortex technology complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex AF cases,” said Nick Spadea-Anello, global president, Electrophysiology, Boston Scientific. “The OptiMap System has demonstrated it can help physicians devise a targeted ablation strategy for complex cases, which can lead to improved procedural efficiency and outcomes in patients with challenging atrial arrhythmias.2 We look forward to advancing this technology and driving future clinical evidence generation with the goal of making it accessible to physicians and patients globally in the years ahead.”

Cortex received U.S. Food and Drug Administration 510(k) clearance for the OptiMap System in 2023 and recently completed the randomized, controlled FLOW-AF clinical trial with data demonstrating that OptiMap-guided treatment of AF sources in patients with persistent AF improved freedom from AF one year after an ablation by 51% compared with patients who received conventional pulmonary vein isolation therapy alone. Earlier this year, the company initiated a 300 patient, global clinical trial, RESOLVE-AF, evaluating the effectiveness of the OptiMap System in identifying extra-pulmonary vein sources.

“Cortex was established to provide physicians with a more intelligent and precise solution for patients with AF,” said Duke Rohlen, chief executive officer, Cortex. “Joining Boston Scientific will allow us to further develop this technology, which we believe has the ability to transform the treatment of AF for patients around the world.”

Boston Scientific expects to complete the transaction in the first half of 2025, subject to customary closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2025 and is expected to be slightly dilutive on a GAAP basis due to amortization expense and acquisition-related net charges. Specific terms of the transaction have not been disclosed.

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced U.S. Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise® Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment.

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years.

In approving the TPT, CMS created a distinct device category and code (C1736: Catheter Renal Denervation, Ultrasound) for Ultrasound Renal Denervation in recognition of the differentiated technology and procedure with the Paradise uRDN System. Additional details and the notice can be found here: https://public-inspection.federalregister.gov/2024-25521.pdf

The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves. The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.

“TPT for ultrasound renal denervation increases access to a proven device-based hypertension treatment option to patients who have been unable to achieve blood pressure control with lifestyle changes and medications alone,” said Lara Barghout, president and CEO of Recor Medical. “The granting of TPT highlights the safety and efficacy of this breakthrough device, which together demonstrated that the Paradise uRDN system met the newness and significant clinical improvement criteria. By creating a distinct Device Category, CMS have also recognized that the Paradise uRDN system is a highly differentiated technology and that there are significant differences in comparison to other technologies available in the marketplace. This is a major step forward in the reimbursement available for the Paradise uRDN system, creating additional financial support for hospitals and physicians to provide this novel and effective therapy to their uncontrolled hypertension patients.”

Hypertension, or high blood pressure, is the leading contributor to disease burden worldwide, resulting in increased cardiovascular morbidity and mortality, poor quality of life, and higher costs to health systems. The U.S. Food and Drug Administration (FDA) approved Recor’s Paradise Ultrasound Renal Denervation system for the treatment of hypertension on November 7, 2023. The Paradise uRDN system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient’s blood pressure.

Jason Whiting Appointed CEO of Avation Medical

Jason Whiting
Jason Whiting, CEO of Avation Medical

Avation Medical, an innovative neuromodulation and digital health company on a mission to make non-invasive, physiologic, closed-loop neuromodulation accessible to patients across a variety of clinical conditions, announced that Jason Whiting has been named as Chief Executive Officer. Mr. Whiting succeeds Jill Schiaparelli, who had served in the role since 2018.

“I am excited to join the Avation Medical team as we accelerate the commercialization of this groundbreaking technology to reach patients across the US by working closely with physicians and payors,” said Whiting. “The Vivally® System is the first non-invasive, physiologic closed-loop neuromodulation treatment offering at-home therapy for the more than 9 million people receiving care for symptoms of overactive bladder (OAB).”

Jason Whiting has more than 25 years of experience in the MedTech industry, driving innovation and adoption of new technologies in the implantable, capital equipment, and wearable markets. Before joining Avation Medical, Mr. Whiting served as President of ZOLL Cardiac Management Solutions for more than 8 years—prior to this, he was Vice President of Marketing and Clinical Operations, beginning in 2008.

“As Avation commercially scales, Jason Whiting will bring valuable experience and leadership that we expect will accelerate growth and profitability,” said Tom Shehab, MD, Chairman of the Avation Medical board of directors. “Jason has successfully brought wearable technologies to market and created new categories in the MedTech space. On behalf of the entire Board, I would like to thank Jill for her service to the organization and her role in guiding the Company to this stage.”

Avation Medical’s Vivally System is a wearable bladder control therapy and digital health system for treating patients with the chronic conditions of OAB, urge urinary incontinence, and urinary urgency — without the need for surgery, needle electrodes, or drugs. It is appropriate for every patient suffering from these bladder issues at any point in the care pathway.

The Vivally System is the only OAB treatment to harness the power of physiologic, closed-loop control with transcutaneous tibial nerve stimulation and continuous EMG sensing. Vivally uses the patient’s own physiologic response to objectively confirm activation of the tibial nerve and continuously monitor nerve recruitment, automatically adjusting the stimulation within a Personalized Therapeutic Range™ to ensure both safety and optimal therapeutic output. The non-invasive therapy and digital health system gives physicians and their staff the opportunity to provide personalized treatments for their patients, who can conduct the therapy at home.

Holiday Stress & Heart Health: How AI-Powered Remote Cardiac Monitoring Redefines Cardiovascular Wellness During High-Stress Seasons | By Stuart Long, CEO, InfoBionic.Ai

Stuart Long
Stuart Long, CEO, InfoBionic.Ai

Stuart Long Advises:

The holiday season, while joyous, can also amplify stress in ways that elevate cardiovascular risk. Emotional stressors can contribute not only to anxiety but also to serious heart health risks, as hormones like cortisol and adrenaline increase blood pressure, heart rate, and inflammation. This isn’t just theory; cardiac fatalities are almost 5% higher during the holiday season, with heart attack rates spiking by 37% on December 24. December 25 has the highest cardiac death rate in the U.S., followed closely by December 26 and January 1.

With these elevated seasonal risks, proactive cardiac monitoring becomes paramount to positive outcomes, especially for patients at higher risk for heart conditions. AI-enabled remote patient monitoring (RPM) has emerged as a solution, providing continuous, near real-time insights that support timely interventions to reduce the risk of stress-induced heart attacks and strokes. By converting fluctuating stress levels into actionable cardiac data, AI-enabled RPM offers improved cardiac outcomes—not only during the holidays but throughout the year.

In this article, we’ll explore the critical connection between stress and heart health, and discuss how AI-powered remote cardiac monitoring can help high-risk individuals avoid preventable cardiac events, especially during the holiday season.

The Connection Between Stress, Anxiety, and Heart Health

Before we examine AI-enabled virtual cardiac telemetry, let’s take a closer look at the physiological impact of stress. Stress affects the body in various ways, and its impact on the cardiovascular system is particularly significant. When a person experiences stress, including the holiday kind, the body’s “fight or flight” response is activated, leading to the release of stress hormones such as cortisol and adrenaline. These hormones cause blood vessels to constrict, increase heart rate, and elevate blood pressure, all of which can strain the heart.

While these responses are beneficial in short bursts—helping people react quickly to threats—chronic activation due to ongoing stress can be harmful. Prolonged, chronic stress leads to inflammation, which plays a key role in the development of cardiovascular diseases. Studies show that people reporting high stress and depression were 2.5 times more likely to have a heart attack than those with low stress or no depression history.

The combination of holiday-related stressors like financial strain, disrupted routines, social obligations, and even changes in diet and alcohol consumption can elevate stress levels, and, by extension, cardiovascular risks—especially for individuals already at heightened risk of heart conditions.

In addition to seasonal stress, the holidays introduce another dynamic that contributes to increased cardiac events. People often delay seeking medical attention, assuming that their symptoms are due to stress, exhaustion, or digestion. This can lead to underreporting of symptoms and missed opportunities for early intervention. For example, a person experiencing chest pain during a holiday dinner might dismiss it as heartburn from a heavy meal, only to face a serious cardiac event soon after. Even if a patient is concerned about their symptoms, they may be inclined to delay treatment until after the holiday rush has subsided. When it comes to cardiac conditions, however, even days can make the difference between a positive outcome and a fatality.

Turning Seasonal Stress into Actionable Cardiac Insights with AI-Enabled Virtual Telemetry

AI-powered RPM is reshaping cardiac care by making proactive management accessible for high-risk patients, especially in times of heightened stress. Unlike low-risk patients, who may benefit from consumer wearables and simple lifestyle changes, high-risk individuals gain an additional layer of protection through continuous monitoring and near real-time analysis, eliminating the need for frequent in-office visits.

Historically, cardiovascular monitoring was limited to episodic check-ups and patient-reported symptoms, which left critical gaps in care. Without continuous monitoring, patients could go years without intervention, allowing disease progression to advance quietly. Traditional, wired devices collected data only intermittently, meaning early warning signs could be missed, and interventions were often reactive, addressing issues only after a heart event had occurred.

Today, AI-driven RPM offers a significant improvement by continuously collecting data and analyzing it in near real-time, shifting cardiac care from reactive to proactive. Streamlined, wireless devices now enable high-risk patients to be monitored as part of their daily lives—whether they’re recovering post-surgery, managing a chronic condition, or facing seasonal stress. AI also analyzes subtle, “non-event” data—patterns that may not cause immediate symptoms but indicate developing issues. This nuanced insight allows both patients and providers to identify risks early and take preventative action, rather than waiting for symptoms to escalate.

Reflecting the increased reliance on AI-enabled RPM and other health technology, the wearable device market reached $33.85 billion in 2023 and is projected to grow at a CAGR of 25.66% from 2024 to 2030, highlighting the rising demand for continuous, proactive health management solutions.

Key Benefits of AI-Powered Remote Monitoring for High-Stress During the Holiday Season

AI-powered remote monitoring systems offer a range of benefits, particularly for high-risk cardiovascular patients who may be more susceptible to stress-induced cardiac events around the holidays. Let’s explore some of the reasons AI-enabled wearable technology is especially beneficial during the festive season:

  1. Continuous, non-intrusive monitoring throughout the season

One of the key advantages of AI-powered remote cardiac telemetry is that these devices provide round-the-clock monitoring without requiring users to manually check their vitals or schedule regular doctor visits. They offer a non-intrusive way of keeping track of health parameters, ensuring that any abnormal readings are immediately flagged, even during holiday travel, shopping, or gatherings.

This constant vigilance is particularly beneficial for high-risk patients, as it allows for early detection and intervention during the most stressful time of the year. It also improves the quality of patients’ long-term health outside the season; one study found a 50% reduction in 30-day readmissions for patients with congestive heart failure using an AI-powered remote monitoring program.

  1. More personalized alerts and interventions for stress management

AI-powered remote cardiac monitoring solutions can deliver personalized health insights based on the patient’s historical data, which is particularly useful when stress levels are higher than usual. This can provide peace of mind, and, in turn, actually reduce stress as a result.

When monitoring solutions detect deviations from a patient’s norm, they can send reminders to practice relaxation techniques, stay hydrated, or take medication. AI-enabled remote cardiac monitoring systems offer the added benefit of automated alerts to the provider, notifying clinicians if patients are experiencing anomalies or indicators of a potential event. AI-enabled devices are also accurate when it comes to detection. In fact, the average F1 score for AI algorithms exceeded that of average cardiologists in arrhythmia detection.

  1. Connecting patients and providers despite the distance

AI-powered RPM enables providers to stay informed about patients’ health without relying solely on in-person visits. If a device identifies a concerning pattern, it can notify the provider, allowing for timely adjustments to the treatment plan. This connectivity is especially valuable during the holidays when patients may be less likely to prioritize medical check-ups, and providers are more likely to take well-deserved vacation time themselves.

Equipped with a high-level of connectivity and flexibility, AI-enabled remote monitoring devices also show long-term improvements in patient adherence during any season, as nearly 89% of patients reported feeling more satisfied with their care when using RPM tools.

Non-intrusive, highly personalized, and continuously connected, virtual cardiac telemetry solutions are enabling a bright and proactive future for cardiology. The future of cardiology is one in which cardiac health is not treated as an isolated clinical function, but instead a fully integrated part of a patient’s lifestyle—complete with the holiday frenzy, the festive eating, and the high-stress family gatherings.

The Future of AI in Cardiovascular Care: For the Holidays and Beyond

The holiday season may bring a spike in stress levels, but it doesn’t have to mean a spike in cardiac events. By redefining the limits of traditional cardiovascular care, AI-powered virtual cardiac telemetry enables healthcare providers and patients to predict and even prevent stress-induced cardiac events, offering peace of mind during stressful seasons. Instead of treating conditions after a major event, the future of cardiology will embrace proactive prevention through the power of detection—by monitoring the nuanced fluctuations of a patient’s heart at all times, especially during periods of intense stress.

As AI technology continues to advance, we will move ever-closer to a world in which stress no longer dictates our cardiac outcomes, and every heartbeat is protected, even during the most stressful times of the year.

Author Bio

Stuart Long has been the CEO of InfoBionic.Ai since March 2017. He underscores the company’s commitment to widespread market adoption of its transformative wireless remote patient monitoring platform for chronic disease management. With more than 25 years of experience in the medical device market, Stuart brings expertise in achieving rapid commercial growth. Learn more about remote cardiac monitoring at www.infobionic.ai.

Carl Marks Securities Successfully Advises Kewaunee Scientific Corporation on $55 Million Acquisition of Nu Aire

Carl Marks Securities, an affiliate of middle market investment bank Carl Marks Advisors, today announced that it has successfully advised Kewaunee Scientific Corporation (“Kewaunee”), a global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, on its acquisition of Nu Aire, a Minneapolis-based manufacturer of equipment for a diverse range of laboratory and pharmacy environments.

Founded in 1906 and headquartered in Statesville, North Carolina, Kewaunee designs and manufactures laboratory, healthcare, and technical furniture products for both domestic and international markets out of facilities in Statesville and Bangalore, India. Kewaunee’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

The acquisition of Nu Aire will provide Kewaunee with a more robust, diversified distribution network to meet global laboratory needs. Nu Aire is a recognized market leader whose product portfolio and well-developed channel strategy complements Kewaunee’s existing offerings.

“The acquisition marks a transformative moment for both companies,” said Chris Parisi, Partner at Carl Marks Advisors. “The combined organization, which is poised to capitalize on secular tailwinds and ongoing global investments in the life sciences, healthcare, and education sectors, will benefit from expanded product offerings and market reach.”

“We have maintained an advisory relationship with Kewaunee for many years and are proud to have played a role in the successful strategic acquisition of Nu Aire by Kewaunee,” added Evan Tomaskovic, Managing Partner at Carl Marks Advisors. “It is gratifying to assist a 100-year-old business complete a key acquisition of a more than 50-year-old family-owned business, fortifying the legacies of both world-class organizations.”

“We are extremely appreciative of Carl Marks Securities’ leadership and guidance throughout the transaction process,” said Thomas D. Hull III, President and Chief Executive Officer at Kewaunee. “Their team played an important role in formalizing our preexisting partnership with Nu Aire, providing us with insights we might not have considered and effective ways to align our businesses to meet the diverse needs of end-users in laboratory furnishings.”

“The acquisition of Nu Aire is a strategic move that will significantly enhance our position in the industry,” added Don Gardner, Chief Financial Officer at Kewaunee. “This achievement would not have been possible without the technical expertise and analytical rigor provided by Carl Marks Securities. Their dedication and in-depth understanding of the complexities of this deal were instrumental in guiding us through every step of the process.”

The Future of Nursing with AI: Studies from Columbia Nursing on Using AI for Nursing Education, Patient Care, Alzheimer’s Detection, and Mental Health

Studies from Columbia Nursing

An Example of Leveraging AI For Documentation: ChatGPT-Generated Nursing Care Plan for an Older Adult With Lung Cancer  

AI can transform how nurses document patient care plans, potentially leading to better health outcomes, according to a new study led by Postdoctoral Research Scientist Fabiana Dos Santos, PhD. However, Santos emphasized careful validation of AI models is essential. The research team developed and validated a method for structuring ChatGPT prompts to generate high-quality nursing care plans. ChatGPT-generated plans prioritized critical aspects of care for a hypothetical lung cancer patient, such as oxygenation, infection prevention, fall risk, and emotional support, while also providing thorough explanations for each suggested intervention, making them valuable tools for nurses.

ADscreen: A Speech Processing-Based Screening System for Automatic Identification of Patients With Alzheimer’s Disease and Related Dementias

A study led by Assistant Professor Maryam Zolnoori, PhD, examined the capabilities of ADscreen, a computerized speech processing algorithm, to assist clinicians in detecting and tracking the progression of Alzheimer’s disease and related dementias (ADRDs). The study looked at how the technology analyzed acoustic and linguistic features in voice recordings of ADRD patients, identifying early cognitive impairment signs. Zolnoori and her colleagues found ADscreen to be sensitive, cost-effective, and easily integrated into clinical workflows for early diagnosis, which could improve treatment outcomes. For the next phase of the study focused on fine-tuning the tool, the research team has been collaborating with VNS Health, one of the nation’s largest home- and community-based health care nonprofits, and where both Zolnoori and her colleague, Associate Professor Maxim Topaz, PhD, of Columbia Nursing, conduct clinical research.

Patient Perspectives on AI for Mental Health Care: A Cross-Sectional Survey Study

Natalie Benda, PhD, assistant professor, Meghan Turchioe, PhD, assistant professor, and colleagues investigated patient perspectives on using AI in mental health care in this study. The survey of 500 U.S. adults found that 49.3% of participants viewed AI as beneficial for mental health care, with African Americans and individuals with lower health literacy more likely to hold this opinion, while women were less likely. The study also revealed that 81.6% of participants believed health care professionals should be responsible for misdiagnoses in mental health conditions. Concerns centered on AI tools leading to incorrect diagnoses, inappropriate treatments, reduced provider interaction, and potential breaches of confidentiality.

A Cross-Sectional Study of Patient Perspectives on Artificial Intelligence: A Comparison of Somatic versus Mental Health Care 

In a follow up study, Benda, Turchioe, and colleagues compared patient views on somatic and mental health AI applications using two national cross-sectional surveys conducted in 2019 and 2022. Participants in the mental health survey expressed greater skepticism towards AI than those in the somatic health survey, although participants in both surveys had high discomfort with AI delivering diagnoses.

Returning Value From the All Of Us Research Program to PhD-Level Nursing Students Using ChatGPT as Programming Support: Results From a Mixed-Methods Experimental Feasibility Study 

ChatGPT could help novice students overcome programming barriers, thus saving time and reducing frustration and cognitive load, a study led by Turchioe, finds. The study examined the feasibility of using generative AI tools, such as ChatGPT, to help teach nursing PhD students coding and programming skills. Students interacted with ChatGPT for help with programming tasks related to data science and visualization. ChatGPT helped novice students complete tasks like building regression models and generating data visualizations faster and with more confidence.

Special Issue on Teaching and Training Future Health Informaticians: Increasing Generative Artificial Intelligence Competency Among Students Enrolled In Doctoral Nursing Research Coursework 

Another study led by Turchioe explored the integration of generative AI tools in health care, focusing on how PhD nursing students can be equipped to assess and use these technologies effectively. The study aimed to develop and evaluate a brief intervention to increase students’ knowledge of AI applications in health care. Researchers introduced generative AI to nursing PhD students through a combination of lectures and laboratory activities. Students completed tasks related to clinical decision support, patient decision support, and scientific communication using ChatGPT. Results showed students identified both strengths and limitations of ChatGPT and reported increased self-rated competency.

Exactech Reports the FDA Clearance of Truliant® Porous 3D Tibial Implant for Knee Replacement Surgery

Exactech

Exactech, a global medical technology leader, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Truliant® Porous Tibial Tray, a 3D tibial knee implant.

The Truliant Porous Tibial Tray leverages additive manufacturing technology to create a porous structure designed to mimic the structure of cancellous bone. This design aims to facilitate both initial and biological fixation, designed to accommodate patients’ active lifestyles.

“With a focus on cementless fixation and increased efficiency, it is no surprise that Truliant Porous is the fastest growing segment of Exactech’s knee portfolio,” said Exactech Chief Marketing Officer and Senior Vice President of Large Joints Adam Hayden. “By expanding our porous offerings with the laser-printed tray, knee surgeons will have access to additional sizing and fixation options for the personalization of their patients’ total knee replacement procedures, improving upon Exactech’s already successful cementless knee.”

Exactech’s Truliant Porous laser-printed 3D tibial tray features peripherally placed tibial pegs, a dual v-channeled keel and optional cancellous bone screws designed to increase initial rotational stability and allow an increased bone-implant interface.

This FDA clearance marks a significant milestone for Exactech, positioning the company to continue to address the growing demand for cementless knee solutions. More here.

Bright Uro Announces Oversubscribed $32M Series A Funding Round

Bright Uro, a medical device company with a mission to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, today announced the second closing of its Series A funding round, which was oversubscribed by nearly 40% above and secured a total of $32M for the company.

Laborie Medical Technologies (Laborie), a leading global provider of urology diagnostic and therapeutic solutions, remains the lead investor, and it is now joined by University of California (UC Investments), Freepoint Capital Group and Laurelin Investors. The additional funding will be used to support Bright Uro’s 2025 anticipated launch of its Glean™ Urodynamics System, as well as manufacturing capacity expansion and R&D activities to support expanding the future pipeline.

“The Glean system has the potential to significantly impact the urodynamics landscape, and we remain very supportive of the Bright Uro team,” said Michael Frazzette, President and CEO of Laborie. “This funding round will help enable improved patient and clinician access to the technology which directly aligns with Laborie’s mission of preserving and restoring human dignity.”

“The overwhelming interest from a diverse range of sophisticated investors is a true testament to the compelling mission we are on,” said Derek Herrera, founder and CEO of Bright Uro. “With this funding, we are well resourced for the launch of Glean in 2025, while also continuing to resource our pipeline of innovation. We have never been more confident in the expected impact Glean will have for clinicians and millions of patients suffering from urinary issues.”

1...345...923Page 4 of 923

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330